We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
(+13%)
Cap. Flow
+$64.9M
Cap. Flow
% of AUM
3.27%
Top 10 Holdings %
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65
Avg Time Held Equity + Options
4.7
quarters
Top 10 Avg Time Held Equity + Options
5.1
quarters
Top 20 Avg Time Held Equity + Options
6.3
quarters
Avg Time Held Equity only
4.9
quarters
Top 10 Avg Time Held Equity only
5.1
quarters
Top 20 Avg Time Held Equity only
6.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$46.6M |
| 2 |
Puma Biotechnology
PBYI
|
+$41M |
| 3 |
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
|
+$35.9M |
| 4 |
CORI
Corium International, Inc.
CORI
|
+$19M |
| 5 |
Intuitive Surgical
ISRG
|
+$17.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aclaris Therapeutics
ACRS
|
+$37.6M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$22.2M |
| 3 |
NEVRO CORP.
NVRO
|
+$20.4M |
| 4 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$13.3M |
| 5 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$12.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.26% |
| 2 | Miscellaneous | 3.45% |
| 3 | Consumer Staples | 0.19% |
| 4 | Consumer Discretionary | 0.06% |
| 5 | Energy | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
PUT
DELISTED
Radius Health, Inc.
RDUS
| $9.05M | 0.46% |
200,000
+190,200
| +1,941% | +$7.27M |
2017 Q1
1 quarter
|
|
52
Sonida Senior Living
SNDA
$1.74B
| $8.06M | 0.41% |
35,345
-3,000
| -8% | -$648K |
2014 Q4
10 quarters
|
|
53
Talphera
TLPH
$56.1M
| $8.02M | 0.4% |
186,567
-83,869
| -31% | -$4.26M |
2013 Q2
16 quarters
|
|
54
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $7.89M | 0.4% |
+100,000
| New | +$8.18M |
2017 Q2
0 quarters
|
|
55
Corbus Pharmaceuticals
CRBP
$102M
| $7.76M | 0.39% |
41,083
-584
| -1% | -$115K |
2015 Q2
8 quarters
|
|
|
SIOX
56
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $6.96M | 0.35% |
37,500
+12,500
| +50% | +$2.19M |
2017 Q1
1 quarter
|
|
57
uniQure
QURE
$1.51B
| $6.75M | 0.34% |
1,090,119
-175,844
| -14% | -$950K |
2014 Q4
10 quarters
|
|
|
VIVE
58
DELISTED
VIVEVE MED INC
VIVE
| $6.39M | 0.32% |
890
-49
| -5% | -$365K |
2017 Q1
1 quarter
|
|
59
CALL
Ultragenyx Pharmaceutical
RARE
$1.51B
| $6.21M | 0.31% |
+100,000
| New | +$6.02M |
2017 Q2
0 quarters
|
|
|
NVTA
60
DELISTED
Invitae Corporation
NVTA
| $6.21M | 0.31% |
649,500
+169,500
| +35% | +$1.67M |
2016 Q4
2 quarters
|
|
61
Zymeworks
ZYME
$1.82B
| $6.1M | 0.31% |
+730,768
| New | +$8.18M |
2017 Q2
0 quarters
|
|
62
ANI Pharmaceuticals
ANIP
$1.69B
| $5.87M | 0.3% |
125,399
-129,490
| -51% | -$6.25M |
2014 Q4
10 quarters
|
|
63
DELISTED
Clearside Biomedical
CLSD
| $5.65M | 0.28% |
41,345
-6,126
| -13% | -$736K |
2016 Q2
4 quarters
|
|
64
UnitedHealth
UNH
$340B
| $5.28M | 0.27% |
28,480
+15,480
| +119% | +$2.71M |
2015 Q4
6 quarters
|
|
|
FOMX
65
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $5.18M | 0.26% |
1,117,324
-205,670
| -16% | -$918K |
2016 Q2
4 quarters
|
|
66
UroGen Pharma
URGN
$1.87B
| $4.86M | 0.24% |
+269,014
| New | +$4.67M |
2017 Q2
0 quarters
|
|
67
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
| $4.29M | 0.22% |
1,259,636
| – | – |
2015 Q2
8 quarters
|
|
|
SRRA
68
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $4.28M | 0.22% |
91,380
-1,213
| -1% | -$61.9K |
2017 Q1
1 quarter
|
|
|
FWP
69
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| $3.96M | 0.2% |
27,817
-22,789
| -45% | -$3.17M |
2016 Q1
5 quarters
|
|
|
NEPT
70
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
| $3.8M | 0.19% |
4,657
| – | – |
2013 Q2
16 quarters
|
|
71
DELISTED
Exact Sciences
EXAS
| $3.54M | 0.18% |
100,000
-310,000
| -76% | -$9.57M |
2017 Q1
1 quarter
|
|
|
PFNX
72
DELISTED
Pfenex Inc.
PFNX
| $3.39M | 0.17% |
845,973
-46,874
| -5% | -$216K |
2014 Q3
11 quarters
|
|
73
Ocugen
OCGN
$321M
| $3.18M | 0.16% |
29,630
| – | – |
2016 Q3
3 quarters
|
|
74
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3M | 0.15% |
+120,000
| New | +$2.76M |
2017 Q2
0 quarters
|
|
75
ADMA Biologics
ADMA
$2.28B
| $2.77M | 0.14% |
721,102
| – | – |
2016 Q3
3 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2017 Portfolio in Review
As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Perceptive Advisors deployed $64.9M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.
- Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
- Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
- Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
- Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
- Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
- Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
- Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.
Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.